Eicosapentaenoic acid 1,800 mg daily significantly reduced total cholesterol from 245 to 213 mg/dL in diabetic patients, and decreased endothelial microparticles while increasing adiponectin in those with high Ang-2 levels.
Does eicosapentaenoic acid improve lipid profiles and endothelial biomarkers in hyperlipidemic patients with and without type 2 diabetes?
Eicosapentaenoic acid (EPA) 1,800 mg daily improves lipid profiles and modulates endothelial biomarkers by decreasing EDMP and Ang-2 while increasing adiponectin in hyperlipidemic patients with type 2 diabetes, suggesting potential anti-atherosclerotic benefits.
Absolute Event Rate: 213% vs 245%
p-value: p=<0.01
AIM: The aim of this study was to evaluate the significance of endothelial cell-derived microparticles (EDMP), angiopoietin-2 (Ang-2) and adiponectin in hyperlipidemic patients with and without type 2 diabetes mellitus, and to compare the two for the effects of eicosapentaenoic acid (EPA) on these markers. METHODS: One hundred and twenty-six hyperlipidemic patients with and without type 2 diabetes mellitus received EPA 1,800 mg daily, and 50 of the patients were non-diabetic. RESULTS: EDMP and Ang-2 levels prior to treatment were higher in diabetic patients than in non-diabetic patients, whereas adiponectin levels were lower in diabetics. When diabetic patients were classified into two groups on the basis of Ang-2 levels, the levels of all markers remained unchanged in those without a high Ang-2 level after EPA treatment. In contrast, all markers except for adiponectin were decreased significantly in diabetic patients with high Ang-2 levels after 6 months of EPA treatment. These diabetic patients with high Ang-2 levels displayed a more significant increase in adiponectin levels after EPA treatment than those who did not. CONCLUSION: These results suggest that EPA possesses an adiponectin-dependent anti-atherosclerotic effect and may be beneficial for the prevention of vascular complications in diabetic patients with high Ang-2 levels.
Nomura et al. (Thu,) conducted a other in Hyperlipidemia with and without type 2 diabetes mellitus (n=126). Eicosapentaenoic acid vs. Baseline was evaluated on Improvement of total cholesterol (TC) within 6 months (p=<0.01). Eicosapentaenoic acid 1,800 mg daily significantly reduced total cholesterol from 245 to 213 mg/dL in diabetic patients, and decreased endothelial microparticles while increasing adiponectin in those with high Ang-2 levels.